Methylseleninic acid is a novel suppressor of aromatase expression

Journal of Endocrinology

Volumn 212, Issue 2, 2012, Pages 199-205

  Gao, Ruijuan ^a   Zhao, Lijuan ^b   Liu, Xichun ^a   Rowan, Brian G ^a   Wabitsch, Martin ^c   Edwards, Dean P ^d   Nishi, Yoshihiro ^e   Yanase, Toshihiko ^f   Yu, Qun ^g   Dong, Yan ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c UNIVERSITY OF ULM   (Germany)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; AROMATASE; AROMATASE INHIBITOR; DEXAMETHASONE; GLUCOCORTICOID; LETROZOLE; MESSENGER RNA; METHYLSELENINIC ACID; SELENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION;

ADENYLATE CYCLASE; ADIPOCYTES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DEXAMETHASONE; DOWN-REGULATION; ENZYME ACTIVATORS; ENZYME INDUCTION; FEMALE; FORSKOLIN; GLUCOCORTICOIDS; HUMANS; NEOPLASM PROTEINS; ORGANOSELENIUM COMPOUNDS; OVARIAN NEOPLASMS; OVARY; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 84863068796     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0363     Document Type: Article

References (60)

1. Agarwal VR, Bulun SE, Leitch M, Rohrich R & Simpson ER 1996 Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. Journal of Clinical Endocrinology and Metabolism 81 3843-3849.
2. Brown KA & Simpson ER 2010 Obesity and breast cancer: progress to understanding the relationship. Cancer Research 70 4-7.
3. Brown KA, McInnes KJ, Hunger NI, Oakhill JS, Steinberg GR & Simpson ER 2009 Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Research 69 5392-5399.
4. Bulun SE, Price TM, Aitken J, Mahendroo MS & Simpson ER 1993 A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. Journal of Clinical Endocrinology and Metabolism 77 1622-1628.
5. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B et al. 2005 Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacological Reviews 57 359-383.
6. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY & Nabholtz JM 2006 Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncology 7 633-643.
7. Charalabopoulos K, Kotsalos A, Batistatou A, Charalabopoulos A, Vezyraki P, Peschos D, Kalfakakou V & Evangelou A 2006 Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA. British Journal of Cancer 95 674-676.
8. Chen S, Masri S, Hong Y, Wang X, Phung S, Yuan YC & Wu X 2007 New experimental models for aromatase inhibitor resistance. Journal of Steroid Biochemistry and Molecular Biology 106 8-15.
9. Chu S, Nishi Y, Yanase T, Nawata H & Fuller PJ 2004 Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells. Molecular Endocrinology 18 1919-1928.
10. Ciolino HP, Dai Z & Nair V 2011 Retinol inhibits aromatase activity and expression in vitro. Journal of Nutritional Biochemistry 22 522-526.
11. Clyne CD, Speed CJ, Zhou J & Simpson ER 2002 Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. Journal of Biological Chemistry 277 20591-20597.
12. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, van de Velde CJ, Delozier T, Alvarez I et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 559-570.
13. Crichton MB, Nichols JE, Zhao Y, Bulun SE & Simpson ER 1996 Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells. Molecular and Cellular Endocrinology 118 215-220.
14. Dong Y, Lee SO, Zhang H, Marshall J, Gao AC & Ip C 2004 Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Research 64 19-22.
15. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240 889-895.
16. Geisler J, Haynes B, Ekse D, Dowsett M & Lonning PE 2007 Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology 104 27-34.
17. Ghosh S, Lu Y & Hu Y 2008 A role of CREB in BRCA1 constitutive promoter activity and aromatase basal expression. International Journal of Biomedical Science 4 260-265.
18. Heneweer M, Muusse M, Dingemans M, de Jong PC, van den Berg M & Sanderson JT 2005 Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicological Sciences 83 257-263.
19. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Lin GS, Miles S & Neugut AI 2010 Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. Journal of Clinical Oncology 28 4120-4128.
20. Hursting SD 2011 Inflammatory talk: linking obesity, NF-kappaB, and aromatase. Cancer Prevention Research 4 285-287.
21. Ip C, 1998 Lessons from basic research in selenium and cancer prevention. Journal of Nutrition 128 1845-1854.
22. Ip C, Thompson HJ, Zhu Z & Ganther HE 2000 In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Research 60 2882-2886.
23. Ip C, Dong Y &Ganther H.E. 2002 Newconcepts in seleniumchemoprevention. Cancer Metastasis Reviews 21 281-289.
24. Irahara N, Miyoshi Y, Taguchi T, Tamaki Y & Noguchi S 2006 Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. International Journal of Cancer 118 1915-1921.
25. Jiang C, Jiang W, Ip C, Ganther H & Lu J 1999 Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Molecular Carcinogenesis 26 213-225.
26. Kijima I, Phung S, Hur G, Kwok SL & Chen S 2006 Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression. Cancer Research 66 5960-5967.
27. Kijima I, Ye J, Glackin C & Chen S 2008 CCAAT/enhancer binding protein delta up-regulates aromatase promoters I.3/II in breast cancer epithelial cells. Cancer Research 68 4455-4464.
28. Kotsopoulos J, Chen Z, Vallis KA, Poll A, Ghadirian P, Kennedy G, Ainsworth P & Narod SA 2010 Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers. Cancer Causes & Control 21 679-687.
29. van Landeghem AA, Poortman J, Nabuurs M & Thijssen JH 1985 Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Research 45 2900-2906.
30. Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett W.C, Gaziano J.M & Ma J 2004 A prospective study of plasma selenium levels and prostate cancer risk. Journal of the National Cancer Institute 96 696-703.
31. Li GX, Lee HJ, Wang Z, Hu H, Liao JD, Watts JC, Combs GF Jr & Lu J 2008 Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 29 1005-1012.
32. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA et al. 2009 Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the American Medical Association 301 39-51.
33. Liu S, Qi Y, Ge Y, Duplessis T, Rowan BG, Ip C, Cheng H, Rennie PS, Horikawa I, Lustig AJ et al. 2010 Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. Molecular Cancer Therapeutics 9 2016-2025.
34. Maccio A, Madeddu C & Mantovani G 2009 Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obesity Reviews 10 660-670.
35. Mahendroo MS, Mendelson CR & Simpson ER 1993 Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. Journal of Biological Chemistry 268 19463-19470.
36. McInnes KJ, Brown KA, Knower KC, Chand AL, Clyne CD & Simpson ER 2008 Characterisation of aromatase expression in the human adipocyte cell line SGBS. Breast Cancer Research and Treatment 112 429-435.
37. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM & Bulun SE 2001 Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively downregulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Research 61 2250-2255.
38. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S et al. 2007 Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Research 67 3945-3954.
39. Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM & Telford J 1997 Regulation of aromatase activity within the breast. Journal of Steroid Biochemistry and Molecular Biology 61 193-202.
40. Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, Saito M, Nomura M, Mukasa C, Okabe T, Goto K et al. 2001 Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology 142 437-445.
41. Ohno S, Yukinawa F, Noda M & Nakajin S 2009 Mono-(2-ethylhexyl) phthalate induces NR4A subfamily and GIOT-1 gene expression, and suppresses CYP19 expression in human granulosa-like tumor cell line KGN. Toxicology Letters 191 353-359.
42. Ohta Y, Kobayashi Y, Konishi S & Hirano S 2009 Speciation analysis of selenium metabolites in urine and breath by HPLC- and GC-inductively coupled plasma-MS after administration of selenomethionine and methylselenocysteine to rats. Chemical Research in Toxicology 22 1795-1801.
43. Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, Clark LC & Marshall JR 2004 A report of high-dose selenium supplementation: response and toxicities. Journal of Trace Elements in Medicine and Biology 18 69-74.
44. Sanderson JT, Letcher RJ, Heneweer M, Giesy JP & van den Berg M 2001 Effects of chloro-s-triazine herbicides and metabolites on aromatase activity in various human cell lines and on vitellogenin production in male carp hepatocytes. Environmental Health Perspectives 109 1027-1031.
45. Sasano H, Anderson TJ, Silverberg SG, Santen RJ, Conway M, Edwards DP, Krause A, Bhatnagar AS, Evans DB & Miller WR 2005 The validation of new aromatase monoclonal antibodies for immunohistochemistry - a correlation with biochemical activities in 46 cases of breast cancer. Journal of Steroid Biochemistry and Molecular Biology 95 35-39.
46. Sedjo R.L. & Devine S 2011 Predictors of non-adherence to aromatase inhibitors among commercially insuredwomenwith breast cancer. Breast Cancer Research and Treatment 125 191-200.
47. Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I & Coombes RC 1989 Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Research 49 2588-2591.
48. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR & Michael MD 1994 Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrine Reviews 15 342-355.
49. Sofi M, Young MJ, Papamakarios T, Simpson ER & Clyne CD 2003 Role of CRE-binding protein (CREB) in aromatase expression in breast adipose. Breast Cancer Research and Treatment 79 399-407.
50. Suzana S, Cham BG, Ahmad RG, Mohd RR, Fairulnizal MN, Normah H & Fatimah A 2009 Relationship between selenium and breast cancer: a case-control study in the Klang Valley. Singapore Medical Journal 50 265-269.
51. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 353 2747-2757.
52. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do K-A, Thall PF et al. 2009 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. Journal of the National Cancer Institute 101 306-320.
53. Wabitsch M, Brenner RE, Melzner I, Braun M, Moller P, Heinze E, Debatin KM & Hauner H 2001 Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. International Journal of Obesity and Related Metabolic Disorders 25 8-15.
54. Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP & Lu J 2009 Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prevention Research 2 484-495.
55. Yang S, Fang Z, Suzuki T, Sasano H, Zhou J, Gurates B, Tamura M, Ferrer K & Bulun S 2002 Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase. Journal of Clinical Endocrinology and Metabolism 87 2336-2345.
56. Zhang J, Wang L, Anderson LB, Witthuhn B, Xu Y & Lu J 2010 Proteomic profiling of potential molecular targets of methyl-selenium compounds in the transgenic adenocarcinoma of mouse prostate model. Cancer Prevention Research 3 994-1006.
57. Zhao Y, Nichols JE, Bulun SE, Mendelson CR & Simpson ER 1995 Aromatase P450 gene expression in human adipose tissue. Role of a Jak/STAT pathway in regulation of the adipose-specific promoter. Journal of Biological Chemistry 270 16449-16457.
58. Zhao Y, Agarwal VR, Mendelson CR & Simpson ER 1996a Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 5739-5742.
59. Zhao Y, Nichols JE, Valdez R, Mendelson CR & Simpson ER 1996b Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Molecular Endocrinology 10 1350-1357.
60. Zhou J, Gurates B, Yang S, Sebastian S & Bulun SE 2001 Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumorsmediated by CCAAT/enhancer binding protein beta. Cancer Research 61 2328-2334.